Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Glycomic Therapeutics Market from 2024 to 2025?

There has been a swift expansion in the size of the glycomic therapeutics market in the past few years. It is projected to rise from $164.71 billion in 2024 to $190.03 billion in 2025, representing a compound annual growth rate (CAGR) of 15.4%. Factors such as a greater understanding of the importance of glycan, a surge in chronic illnesses, the creation of drugs for uncommon diseases, and partnerships in glycomics research have contributed to the growth experienced in the historic period.

What Is the Projected Market Size of the Glycomic Therapeutics Market?

The market for glycomic therapeutics is projected to experience considerable growth in the coming years, ballooning to a size of $361.09 billion in 2029 with a CAGR of 17.4%. This anticipated growth within the forecast period is due to the increased understanding of glycan biology, the application of precision medicine, growing interest in immunotherapy, heightened funding for research into rare diseases, and the emergence of glycan biomarkers. Key trends set to shape the forecast period include the wider use of glycomic applications within oncology, glycoengineering to enhance therapeutic proteins, the integration of glycomics in immuno-oncology, glycomics applied to rare and genetic disorders, and regulatory considerations pertaining to glycomic drugs.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11894&type=smp

Who are the Major Competitors in the Glycomic Therapeutics Market Outlook?

Major companies operating in the glycomic therapeutics market include F Hoffmann-La Roche Ltd., Bayer AG, Sanofi SA, Thermo Fisher Scientific Inc., GlaxoSmithKline plc, Merck KGaA, ICON plc, Agilent Technologies Inc., AMS Bio, Shimadzu Corporation, Waters Corporation, Bruker Corporation, BioMarin Pharmaceutical Inc., Bio Techne Corp., Promega Corporation, Halozyme Therapeutics Inc., Takara Bio Inc., Vector Laboratories, New England Biolabs Inc., Protalix Biotherapeutics Inc., Genovis AB, Ray Biotech Life Inc., IEC Group, Ludger Ltd, Z Biotech LLC, Alzheon Inc., GlycoMar Limited

What Is Fueling Growth in the Glycomic Therapeutics Market?

The escalation in the number of diabetes cases is predicted to influence the expansion of the glycomic therapeutics market positively. Diabetes, a persistent health issue, impacts the body’s capacity to manage blood sugar (glucose) levels. Changes in glycans, witnessed in diabetes, may result in insulin resistance and other metabolic disorders. Unique glycan patterns are utilized as diabetes biomarkers, aiding in diagnosis, forecasting its advancement, and tracking the reaction to treatments. For instance, the IDF Diabetes Atlas, a Belgium-based worldwide resource that offers comprehensive information and insights into diabetes prevalence, stated in March 2022 that there is a projected rise in global diabetes from 643 million in 2030 to 783 million by 2045, an additional 140 million cases. Consequently, the glycomic therapeutics market’s expansion is supported by the escalating prevalence of diabetes.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=11894&type=smp

Which Glycomic Therapeutics Market Segments Are Growing the Fastest?

The glycomic therapeutics market covered in this report is segmented –

1) By Class: Isolated, Synthetic

2) By Structures: Glycoproteins, Targeting Sialic Acid, Proteoglycans, Targeting Glycosaminoglycans, Glycosylphosphatidylinositol (GPI)-Anchored Proteins And Heparin Based Glycans, Targeting Glycosphingolipids, Other Structures

3) By Mode Of Action: Inhibits Neuraminidase, Inhibits Heparanase And Selectins And Blocks Interactions Between Growth Factors And Heparan Sulfate, Erythropoietin And Enzyme Replacement Therapy (ERT), Tissue Plasminogen Activator, Inhibits Glucosylceramide Synthase, Interleukin 1, 2 And 3, Beta And Gamma Interferons, Other Mode Of Action

4) By Indications: Thrombosis And Chemoprophylaxis, Anemia, Anti-Adhesive And Anti-Inflammatory, Cataracts, Gaucher’s Disease, Mps-1 And IV, Cancer, Alzheimer’s Disease, Influenza Type A And B, Other Indications

Subsegments:

1) By Isolated: Natural Glycans, Glycan Derivatives, Glycoproteins

2) By Synthetic: Chemically Synthesized Glycans, Recombinant Glycans, Glycopeptides

Which Industry Trends Are Shaping the Future of the Glycomic Therapeutics Market?

One of the growing trends in the glycomic therapeutics field is product innovation. Many prominent firms in this sector are concentrating on creating innovative and technologically advanced solutions to fortify their market standing. Case in point, Glenmark Pharmaceuticals Limited, a pharmaceutical corporation based in India, is exploring cutting-edge therapies. In April 2022, it introduced a unique fixed-dose combination (FDC) of a DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor), Teneligliptin, and Pioglitazone. This combination aims to enhance glycemic control and minimize insulin resistance in patients suffering from type 2 diabetes.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/glycomic-therapeutics-global-market-report

Which Countries Are Leading the Glycomic Therapeutics Market?

North America was the largest region in the glycomic therapeutics in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glycomic therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11894

This Report Delivers Insight On:

1. How big is the glycomic therapeutics market, and how is it changing globally?

2. Who are the major companies in the glycomic therapeutics market, and how are they performing?

3. What are the key opportunities and risks in the glycomic therapeutics market right now?

4. Which products or customer segments are growing the most in the glycomic therapeutics market?

5. What factors are helping or slowing down the growth of the glycomic therapeutics market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model